Copyright
©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4690-4699
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Table 4 Proportions of participants with undetectable levels of hepatitis B virus DNA (< 20 IU/mL) in the two groups
HBeAg-positive CHB | HBeAg-negative CHB | |||||
Group | n | 72 wk | 96 wk | n | 72 wk | 96 wk |
A | 114 | 74 (64.91) | 81 (71.05) | 47 | 40 (85.11) | 41 (87.23) |
B | 118 | 81 (68.64) | 92 (77.97) | 51 | 48 (94.12) | 48 (94.12) |
P value | 0.5788 | 0.2326 | 0.1877 | 0.3046 |
- Citation: Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699
- URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4690.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4690